News
-
HeartWare International Reports Third Quarter 2011 Revenues Of $21.3M; 54% Increase From $13.8M In Third Quarter 2010
11/8/2011
HeartWare International, Inc. (NASDAQ: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced revenues of $21.3 million for the third quarter ended September 30, 2011.
-
Merck Announces Presentation Of Phase III Investigational Studies Evaluating DULERA® (Mometasone Furoate And Formoterol Fumarate Dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
10/27/2011
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the efficacy and safety of two dose strengths of DULERA® (mometasone furoate and formoterol fumarate dihydrate) in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease (COPD).
-
Sanofi Pasteur Starts Shipping New Intradermal Influenza Vaccine With 90 Percent Smaller Needle
9/22/2011
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that it began shipping the new Fluzone® Intradermal (Influenza Virus Vaccine) in the U.S.
-
Hospira Announces Positive Results From Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients
9/7/2011
Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced positive results from a Phase I U.S. clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia.
-
Lexicon To Provide Clinical Pipeline Update And Report Second Quarter 2011 Financial Results
8/8/2011
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that it will release its second quarter 2011 financial results on Monday, August 8, 2011 after the financial markets close.
-
Nabi Biopharmaceuticals Announces Results Of First NicVAX® Phase III Clinical Trial
7/25/2011
Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that NicVAX® (Nicotine Conjugate Immunotherapeutic) did not meet its primary endpoint in the company's first of two confirmatory Phase III clinical trials.
-
Isis Initiates Phase 1 Study Of ISIS-PTP1BRx To Treat Type 2 Diabetes
7/25/2011
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.
-
Cardiology Researcher Dr. Wojciech Zareba Addresses Need To Improve Risk Stratification Of Heart Failure Patients Eligible For ICD Or CRT-D
6/29/2011
Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.
-
Pharmacyclics Reports Recent Developments From Clinical Studies Of Its Btk Inhibitor PCI-32765
6/6/2011
Pharmacyclics, Inc. (Nasdaq: PCYC) today announced data from the oral presentation of the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma (CLL/SLL) at the 2011 American Society of Clinical Oncology Annual Meeting.
This website uses cookies to ensure you get the best experience on our website. Learn more